ANGPTL8 and metabolic dysfunction-associated steatotic liver disease: Similarly, circulating ANGPTL8 levels were not significantly higher amongst patients in the NAFLD moderate-to-severe subgroup compared to the controls (SMD: 0.77, 95% CI: -3.25, 4.79, p = 0.25; I2 = 47%).